Welcome back to Research Weekly.
The first day of the FDA’s closely watched peptide meeting has concluded—and the results went against the recommendations made by FDA staff.
On July 23, the Pharmacy Compounding Advisory Committee voted in favor of adding the reviewed BPC-157, KPV, TB-500 and MOTS-C substances to the FDA’s 503A Bulks List.
That recommendation could eventually allow eligible pharmacies to use the substances when compounding prescription products under Section 503A.
But the most important point is this:
FDA Advisory Panel Recommends Four Peptide Groups for Compounding List
Yesterday, the FDA’s Pharmacy Compounding Advisory Committee completed the first day of its closely watched review of seven peptide groups.
After hours of presentations, public comments and committee discussion, the panel recommended adding all four peptide groups reviewed Thursday to the 503A Bulks List.
Day One vote results
BPC-157: 8 in favor, 6 opposed, 1 abstention
KPV: 8 in favor, 6 opposed, 1 abstention
TB-500: 8 in favor, 6 opposed, 1 abstention
MOTS-C: 7 in favor, 5 opposed, 2 abstentions
The committee considered the related free-base and acetate forms of each peptide group. The relatively close results show that the panel remained divided over the strength of the available evidence and the best way to address the existing peptide market.
What the vote actually means...
Yesterday’s recommendations are significant, but they are not FDA approvals.
The committee is an advisory body. Its recommendations will now be considered by the FDA, but the agency is not required to follow them and will make the final regulatory decision.
The votes also do not establish that these compounds are safe, effective or approved for treating any medical condition. Compounded drugs are not FDA-approved and do not undergo the same premarket review for safety, effectiveness and quality as approved drugs.
In practical terms, the panel recommended that the substances become eligible for use in traditional pharmacy compounding under the requirements of Section 503A.
That is very different from approving a finished drug product.
What is the 503A Bulks List?
Section 503A applies to certain traditional compounding performed by state-licensed pharmacists, physicians and eligible facilities.
When a substance is not covered by an applicable USP or National Formulary monograph and is not already a component of an FDA-approved drug, appearing on the 503A Bulks List can allow it to be used in compounding under specified federal conditions.
Bulk substances must also meet additional requirements, including being accompanied by a valid certificate of analysis and coming from an establishment registered with the FDA.
Inclusion does not mean:
The peptide is FDA-approved
Every finished compounded preparation is approved
The substance has been proven safe or effective
Any particular medical claim has been accepted by FDA
Compounding may occur without federal and state restrictions
The distinction is important because headlines describing the committee as “approving peptides” can give readers the wrong impression.
The panel recommended a change in compounding status, not approval of the substances as finished medications.
Three More Peptide Groups Face the Committee Today...
The committee reconvenes today to review:
Emideltide, also known as DSIP
Semax
Epitalon
As with Thursday’s substances, the committee is considering both the free-base and acetate forms. FDA staff has proposed that none of the three groups be added to the 503A Bulks List.
What we are watching today...
The largest questions include:
Whether today’s votes follow the pattern established Thursday
How the committee evaluates limited or older human research
How heavily members weigh community demand and reported experiences
Whether identity and characterization concerns differ between substances
Whether the committee distinguishes between free-base and acetate forms
What timeline FDA provides for its final decisions
This edition was prepared Friday morning before the Day Two votes were completed. We will cover the remaining results and any announced next steps in the next edition of Research Weekly.
Spotlight: AOD-9604 (Advanced Obesity Drug-9604)
Originally developed in the 1990s by Monash University in Australia with the primary goal of isolating hGH's fat-burning capabilities while eliminating its unwanted hormonal side effects
AOD-9604 is designed to affect metabolism locally rather than systemically:
Stimulates Lipolysis: It accelerates the breakdown of stored fat within adipose tissue.
Inhibits Lipogenesis: It prevents the transformation of non-fatty foods into body fat.Beta-3 Adrenergic Receptor Binding: It interacts primarily with beta-3 adrenergic receptors on fat cells to upregulate fat oxidation.
Bypasses the GH Axis: It does not activate growth hormone receptors, meaning it does not cause tissue overgrowth, raise insulin-like growth factor 1 (IGF-1), or alter blood sugar levels.
Clinical Efficacy & Current Research
While animal models demonstrated highly successful fat-mass reduction without requiring a caloric deficit, human trials have yielded mixed results:
Early Success: Early 12-week human trials showed a modest but statistically significant average weight loss of 2.6 kg (compared to 0.8 kg for the placebo group).
Phase IIb Failure: A larger, 24-week Phase IIb clinical trial involving 536 subjects failed to meet its primary endpoint, showing no significant weight-loss efficacy compared to a placebo.
Secondary Applications: Some exploratory research and boutique clinics investigate AOD-9604 for auxiliary properties, such as cartilage restoration and joint repair, though definitive human data remains sparse.
Safety Profile
Data from six randomized, double-blind, placebo-controlled human trials encompassing over 900 participants established a robust safety history:
High Tolerability: Adverse events reported (like mild headaches or minor GI distress) were statistically indistinguishable from the placebo group.
No Antibody Production: None of the tested trial participants developed anti-AOD-9604 antibodies.
Metabolic Safety: Unlike traditional growth hormone therapies, it does not induce glucose intolerance or insulin resistance.
0 comments